Oragenics, Inc.
Sağlık
NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.
$0.22
Price (1 Year)
Participation Finance Screening Ratios
Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.
About the Company
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
WebsiteAnalysis (Turkish): OGEN Hissesi Caiz mi, Helal mi? Oragenics, Inc. Katılım Analizi